PROTOPAM INJECTION Rx
Generic Name and Formulations:
Pralidoxime chloride 1000mg/vial; pwd for IV inj or infusion (IM or SC inj may be used if IV route is not feasible) after reconstitution.
Indications for PROTOPAM INJECTION:
Treatment of poisoning due to pesticides and chemicals (eg, nerve agents) of the organophosphate class which have anticholinesterase activity. In the control of overdosage by anticholinesterase drugs used in the treatment of myasthenia gravis.
Organophosphate poisoning: Slow IV infusion or inj: initially 1000–2000mg over 15–30min; may give second dose after about 1hr if muscle weakness has not been relieved. Additional doses may be given every 10–12hrs if muscle weakness persists. IM dosing: Mild symptoms: 600mg. Wait 15 minutes, if symptoms persist give second dose; wait another 15 minutes, if symptoms persist give third dose. If at any time after first dose, severe symptoms develop, administer two additional 600mg doses in rapid succession for total cumulative dose of 1800mg. Severe symptoms: give three 600mg IM doses in rapid succession for a total dose of 1800mg; if symptoms persist, the series may be repeated beginning approx. 1hr after giving last injection. Anticholinesterase overdosage: 1000–2000mg IV followed by increments of 250mg every 5 minutes.
Organophosphate poisoning: <16yrs: IV dosing: May give loading dose of 20–50mg/kg (not to exceed 2000mg/dose) over 15–30min followed by continuous infusion of 10–20mg/kg/hr; or, give intermittent infusion of 20–50mg/kg over 15–30min, a second dose may be given after about 1 hour if muscle weakness has not been relieved. Repeat dosing every 10–12hrs if needed. IM dosing: Mild symptoms: <40kg: 15mg/kg; ≥40kg: use adult dose. Wait 15 minutes, if symptoms persist give second dose; wait another 15 minutes, if symptoms persist give third dose. If at any time after the first dose, severe symptoms develop, administer two additional weight-based doses in rapid succession. Severe symptoms: give three weight-based doses as three injections in rapid succession into anterolateral thigh (total dose per 3-inj course: 45mg/kg); if symptoms persist, the series may be repeated beginning approx. 1hr after giving last injection.
Not for treating poisoning due to phosphorus, inorganic phosphates, or organophosphates not having anticholinesterase activity. Not an antidote for intoxication by pesticides of the carbamate class. May precipitate myasthenic crisis when treating organophosphate overdosages in cases of myasthenia gravis. Renal insufficiency. Pregnancy (Cat.C). Nursing mothers.
Concomitant atropine: atropinization may occur earlier.
Blurred vision, diplopia, impaired accommodation, dizziness, headache, drowsiness, nausea, tachycardia, increased BP, hyperventilation, muscular weakness, inj site pain, elevated LFTS, transient elevations in creatinine phosphokinase.
Single-use vials (20mL)—6
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|